On Oct. 13, 2020, RedHill Biopharma announced collaborations with two specialist pharmaceutical manufacturers in Europe and Canada to ramp-up manufacturing of opaganib, then in swiftly progressing global Phase 2/3 and U.S. Phase 2 studies for severe COVID-19 pneumonia, to support potential emergency use applications and subsequent demand.